OGDH is required for AML progression in vivo. (A) Schematic of in vivo knockdown experiment using transplantation of shRNA-transduced Nras^G12D; MLL-AF9 AML. (B) Leukemia burden after shRNA knockdown of Ogdh in MLL-fusion AML. Nras^G12D; MLL-AF9 AML clones transduced with retroviruses encoding doxycycline-inducible shControl or shOgdh were transplanted into sublethally irradiated recipient mice. Luminescence imaging was performed before (day 4) and 6 days after treatment with doxycycline vs vehicle (day 10). (C) Quantification of average radiance for the bioluminescence imaging shown in panel B. P values indicated (1-way ANOVA with Sidak multiple comparisons test; n = 5 per condition). (D) Survival curves are shown, and P values are indicated (log-rank test; n = 5-7 per condition). (E) Schematic of in vivo knockdown experiment using transplantation of shRNA-transduced p53^R172H AML. (F) Leukemia burden after shRNA knockdown of Ogdh in p53-mutant AML. p53^R172H AML clones transduced with retroviruses encoding doxycycline-inducible shControl or shOgdh were transplanted into sublethally irradiated recipient mice. GFP⁺ percentage in peripheral blood was measured at day 14. P values indicated (1-way ANOVA with Sidak multiple comparisons test; n = 7-8 per condition). Avg., average; max, maximum; min, minimum; Neo, neomycin resistance cassette; ns, not significant; p, photons; pre-tx, pre-treatment; puro, puromycin resistance cassette; PGK, phosphoglycerate kinase 1 promoter; rtTA, reverse tetracycline-controlled transactivator; s, seconds; sr, steradian; TRE, tetracycline response element.